StockNews.com began coverage on shares of Trinity Biotech (NASDAQ:TRIB – Free Report) in a research note published on Tuesday morning. The brokerage issued a buy rating on the stock.
Trinity Biotech Trading Up 0.8 %
TRIB traded up $0.02 on Tuesday, hitting $2.59. 5,091 shares of the company’s stock traded hands, compared to its average volume of 64,534. The company’s 50 day simple moving average is $2.60 and its 200-day simple moving average is $2.25. The firm has a market cap of $19.74 million, a price-to-earnings ratio of -0.93 and a beta of 1.30. Trinity Biotech has a one year low of $1.49 and a one year high of $4.59.
Trinity Biotech (NASDAQ:TRIB – Get Free Report) last released its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) earnings per share (EPS) for the quarter. The business had revenue of $14.70 million during the quarter. As a group, equities analysts anticipate that Trinity Biotech will post -2.16 EPS for the current fiscal year.
About Trinity Biotech
Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Recommended Stories
- Five stocks we like better than Trinity Biotech
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Cassava Sciences: A Hot Stock to Trade, Invest, or Avoid?
- Which Wall Street Analysts are the Most Accurate?
- MarketBeat Week in Review – 8/5 – 8/9
- What is the Dogs of the Dow Strategy? Overview and Examples
- The Cannabis Sector: Profitability Takes Center Stage
Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.